These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 29419393)
21. Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors. Cicero AFG; Toth PP; Fogacci F; Virdis A; Borghi C Nutr Metab Cardiovasc Dis; 2019 May; 29(5):527-529. PubMed ID: 30954414 [No Abstract] [Full Text] [Related]
22. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825 [TBL] [Abstract][Full Text] [Related]
23. Statement for Appropriate Clinical Use of PCSK9 Inhibitors. Nohara A; Ohmura H; Okazaki H; Ogura M; Kitagawa K; Koseki M; Sato K; Tsukamoto K; Yamashita S; J Atheroscler Thromb; 2018 Aug; 25(8):747-750. PubMed ID: 29899173 [No Abstract] [Full Text] [Related]
24. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Landmesser U; Chapman MJ; Stock JK; Amarenco P; Belch JJF; Borén J; Farnier M; Ference BA; Gielen S; Graham I; Grobbee DE; Hovingh GK; Lüscher TF; Piepoli MF; Ray KK; Stroes ES; Wiklund O; Windecker S; Zamorano JL; Pinto F; Tokgözoglu L; Bax JJ; Catapano AL Eur Heart J; 2018 Apr; 39(14):1131-1143. PubMed ID: 29045644 [No Abstract] [Full Text] [Related]
25. [Up to date lipid lowering treatment]. Paragh G; Karádi I Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517 [TBL] [Abstract][Full Text] [Related]
26. Rapid resolution of xanthelasmas after treatment with alirocumab. Civeira F; Perez-Calahorra S; Mateo-Gallego R J Clin Lipidol; 2016; 10(5):1259-61. PubMed ID: 27678444 [TBL] [Abstract][Full Text] [Related]
27. Eligibility for treatment with PCSK9 inhibitors among patients with stable coronary artery disease presumed to be on maximum hypolipidaemic therapy. Rallidis LS; Triantafyllis AS; Iliodromitis E Hellenic J Cardiol; 2018; 59(5):293-295. PubMed ID: 29128548 [No Abstract] [Full Text] [Related]
28. Familial hypercholesterolaemia: different perspectives. Jones JL; Lakasing E; Archontakis S Nurs Stand; 2009 Aug 19-25; 23(50):35-8. PubMed ID: 19736707 [TBL] [Abstract][Full Text] [Related]
29. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824 [TBL] [Abstract][Full Text] [Related]
31. Genetic screening for familial hypercholesterolemia identifies patients not meeting cholesterol treatment guidelines. Jones LK; Jefferson CR; Chen N; Murray MF Coron Artery Dis; 2021 Sep; 32(6):588-589. PubMed ID: 33394692 [No Abstract] [Full Text] [Related]
32. Inhibition of PCSK9: is this the way forward for managing residual risk? Chowdhury SR; Rees A Curr Opin Lipidol; 2012 Oct; 23(5):509-10. PubMed ID: 22964999 [No Abstract] [Full Text] [Related]
33. [Clinical manifestations of heterozygote familial hypercholesterolemia in Spain. Study of 301 cases from the central and northern areas]. Garcés C; Rodríguez Artalejo F; Serrano A; González Bonillo J; Almagro F; Garrido JA; Zúñiga M; de Oya M Med Clin (Barc); 2000 Jan; 114(2):50-1. PubMed ID: 10702948 [TBL] [Abstract][Full Text] [Related]